LATEST
Sat, Sep 19, 2026
Loading weather...
Markets

Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc d...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia. The results were presented at the Psych Congress in New Orleans, Louisiana.

SOURCE: Nasdaq
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

Sugar Prices Undercut by Demand Concerns

October NY world sugar #11 (SBV26 ) on Friday closed down -0.06 (-0.34%) on Frid...

Read Article »

New York Builds Data Team to Target Consumer Ripoffs

New York City is building a 36-person bureau of data scientists, technologists a...

Read Article »

Rocket Lab's $2.36 Billion Backlog Says More Than Its Stock Price Does

Rocket Lab (NASDAQ: RKLB) is proving it can win major defense spacecraft program...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.